Moreland L W
Department of Medicine, Multipurpose Arthritis Center, University of Alabama at Birmingham, 35294-7201, USA.
J Rheumatol Suppl. 1999 May;57:7-15.
Clinical trials of tumor necrosis factor (TNF) inhibitors for rheumatoid arthritis (RA) have produced consistently outstanding results with no major side effects in patients refractory to other available treatments. The improvement, determined using either the Paulus or the American College of Rheumatology evaluation criteria, is rapid and has persisted over the 2 years of followup data currently available. Trials of 2 drugs are reviewed--infliximab, currently approved for treatment of Crohn's disease, and etanercept, recently approved for RA therapy.
肿瘤坏死因子（TNF）抑制剂用于类风湿性关节炎（RA）的临床试验已取得了持续显著的成果，对于其他现有治疗方法无效的患者也没有重大副作用。使用保卢斯或美国风湿病学会评估标准确定的病情改善迅速，并且在目前可得的两年随访数据中持续存在。本文综述了两种药物的试验——英夫利昔单抗（目前已获批用于治疗克罗恩病）和依那西普（最近已获批用于RA治疗）。
